Product Center
The Phase I Clinical Launch Meeting of the 23-Valent Pneumococcal Polysaccharide Vaccine Was Successfully Held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24
- Views:
(Summary description)The golden autumn is refreshing, and the fruits are fragrant. In this harvest season, we usher in a promising new chapter. The sound of the song is far away, and the Qi River is flowing. In Qi County, Hebi City, Henan Province, a famous historical and cultural city in China, the launch meeting of the Phase I clinical research project of the 23-valent pneumococcal polysaccharide vaccine, jointly developed by Ab&B Bio-Tech Co., Ltd. JS and Beijing Huaan Kechuang Biotechnology Co., Ltd., was successfully held.
The Phase I Clinical Launch Meeting of the 23-Valent Pneumococcal Polysaccharide Vaccine Was Successfully Held
(Summary description)The golden autumn is refreshing, and the fruits are fragrant. In this harvest season, we usher in a promising new chapter. The sound of the song is far away, and the Qi River is flowing. In Qi County, Hebi City, Henan Province, a famous historical and cultural city in China, the launch meeting of the Phase I clinical research project of the 23-valent pneumococcal polysaccharide vaccine, jointly developed by Ab&B Bio-Tech Co., Ltd. JS and Beijing Huaan Kechuang Biotechnology Co., Ltd., was successfully held.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24 16:08
- Views:
The golden autumn is refreshing, and the fruits are fragrant. In this harvest season, we usher in a promising new chapter. The sound of the song is far away, and the Qi River is flowing. In Qi County, Hebi City, Henan Province, a famous historical and cultural city in China, the launch meeting of the Phase I clinical research project of the 23-valent pneumococcal polysaccharide vaccine, jointly developed by Ab&B Bio-Tech Co., Ltd. JS and Beijing Huaan Kechuang Biotechnology Co., Ltd., was successfully held.
The kick-off meeting was presided over by Wang Yanxia, Deputy Director of the Henan Provincial Center for Disease Control and Prevention. Leaders such as Guo Wanshen, Director of the Henan Provincial Center for Disease Control and Prevention, and Zhu Jiangbo, Deputy Mayor of Qi County, attended the kick-off meeting and delivered important speeches. Mr. An Youcai, Chairman and General Manager of Ab&B Bio-Tech Co., Ltd. JS, gave a detailed introduction to the company's development and vaccine overview.
The kick-off meeting organized detailed training and drills for this clinical program. Dr. Shi Weiwei from Beijing Huaan Kechuang Biotechnology Co., Ltd. conducted the 23-valent pneumococcal polysaccharide vaccine researcher's manual training; Mr. Wang Yanxia, Deputy Director of the Henan Provincial Center for Disease Control and Prevention, conducted the quality management standard for drug clinical trials (GCP) and the clinical trial program training for this project; Mr. Zhang Wei from the Henan Provincial Center for Disease Control and Prevention explained the clinical quality control of vaccines and related standard operating procedures; Mr. Guo Qi, project manager of Beijing Zhongsheng Hengyi Pharmaceutical Technology Co., Ltd., a clinical supervision agency, conducted training on clinical research operation procedures.
At the Qixian County Center for Disease Control and Prevention, the participants took part in the on-site simulation exercise and completed a series of tasks such as on-site simulated reception, informed consent, sample collection, physical examination and inquiry, random allocation, vaccination, and post-vaccination observation by functional area. Adhering to the principle of "all for the subjects" during the exercise, they always followed the requirements of the regulations to carry out tasks carefully, meticulously, and comprehensively, and identified and corrected problems in a timely manner. Through the on-the-spot simulation drills, it was ensured that every tester could complete the clinical trial skillfully and efficiently.
"When the winds are favorable, set sail and brave the waves." Ab&B Bio-Tech Co., Ltd. JS will continue to uphold the work spirit of being rigorous, serious, pragmatic, self-disciplined, and always persisting in struggle. We will seek well-being!
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
